Logo
x

Search category

Subscribe Now

GenFleet Therapeutics

The NMPA Accepts GenFleet Therapeutics’ NDA for GFH925 and Grants Priority Review for Lung Cancer

The NMPA Accepts GenFleet Therapeutics’ NDA for GFH925 and Grants Priority Review for Lung Cancer

  • November 27, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.